Illumina, Inc. (ILMN)
|Net Income (ttm)||768.00M|
|Day's Range||433.00 - 449.99|
|52-Week Range||260.42 - 555.77|
|Price Target||459.00 (+4.8%)|
|Est. Earnings Date||Oct 28, 2021|
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers i... [Read more...]
In 2020, Illumina's revenue was $3.24 billion, a decrease of -8.58% compared to the previous year's $3.54 billion. Earnings were $656.00 million, a decrease of -34.53%.Financial Statements
According to 19 analysts, the average rating for Illumina stock is "Hold." The 12-month stock price forecast is 459.00, which is an increase of 4.79% from the latest price.
U.S. life sciences company Illumina said on Monday that it had anticipated an order from EU antitrust enforcers to keep recently acquired Grail as a separate company while waiting for regulatory clearan...
EU antitrust regulators on Monday announced interim measures against U.S. life sciences company Illumina for for closing its $8 billion cash-and-stock takeover of cancer detection test maker Grail deal ...
SAN FRANCISCO--(BUSINESS WIRE)--Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 mil...
SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator.
SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) elevates climate action goals with commitments for net zero greenhouse gas emissions aligned with the Paris Agreement, commits to v...
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recombination...
The gene-sequencing giant sees a huge opportunity in diagnostics.
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...
Two Republican lawmakers on Thursday questioned the Federal Trade Commission's efforts to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging the regulator was not...
SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Morgan Stanley 19th Annual Global Health...
According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.
The U.S. Federal Trade Commission on Tuesday said it seeks to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging it would harm innovation and boost prices.
These growth stocks could boost growth portfolios in the coming quarters The post 7 Great Growth Stocks to Buy Now to Build Your Portfolio appeared first on InvestorPlace. More From InvestorPlace Stock ...
The stock price of Illumina, a gene sequencing company, reached an all-time high of $524 earlier this month before a recent sell-off drove the stock price down 6% to its current level of around $487. IL...
Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.
Illumina CEO on why the company moved forward with Grail deal, in spite of FTC challenge
Frances deSouza, Illumina CEO, joins Power Lunch to discuss his company's deal to buy cancer diagnostics company Grail, in spite of a challenge from the FTC. For access to live and exclusive video from ...
U.S. life sciences company Illumina could face a hefty fine for jumping the gun by completing its $8 billion cash-and-stock takeover of cancer detection test maker Grail without first securing EU antitr...
The genetic-testing company just blatantly defied its regulators.
In defiance of FTC and EU scrutiny, Illumina Inc (NASDAQ: ILMN) went ahead to complete its $8 billion acquisition of Grail. The finalization of the buyout comes as the FTC sued to block the move in Marc...
Illumina Inc has completed its $7.1 billion acquisition of cancer detection test maker Grail Inc, it said on Wednesday amid challenges posed by the U.S. Federal Trade Commission and the European Union a...
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but wi...